Lack of bloodflow to the heart and brain when the heart is stopped during heart surgery can
cause damage to those organs. We hypothesize that a single dose of erythropoietin prior to
the heart bypass portion of surgery may protect the infant human heart and brain from injury.
This randomized clinical trial will involve 120 children, age 6 weeks to 18 years, requiring
heart bypass surgery for congenital heart defects.
Phase:
N/A
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborators:
Children's Hospital and Health System Foundation, Wisconsin National Center for Research Resources (NCRR)